查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961430

口服固態製劑契約製造市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、最終用戶、地區和競爭對手分類，2021-2031年

Oral Solid dosage Contract Manufacturing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球口服固態製劑（OSD）契約製造市場預計將從 2025 年的 410.2 億美元大幅成長至 2031 年的 607.7 億美元，複合年成長率為 6.77%。

在這個領域，片劑和膠囊等固態劑型的生產外包給專業的第三方供應商。推動該市場發展的主要因素是製藥公司為提高成本效益、獲取複雜化合物的先進技術所做的努力，而這些技術無需大量的資本投入。此外，隨著主要藥物專利到期，提高外部生產能力以應對學名藥的大規模生產變得至關重要。根據美國可及藥品協會（Association for Accessible Medicines）預測，到2024年，學名藥和生物類似藥將占美國所有處方箋的90%，凸顯了推動契約製造產業發展的巨大需求。

市場概覽
預測期 2027-2031
市場規模：2025年 410.2億美元
市場規模：2031年 607.7億美元
複合年成長率：2026-2031年 6.77%
成長最快的細分市場 顆粒
最大的市場 北美洲

然而，由於全球法規環境嚴格，該產業面臨許多挑戰。契約製造製造商必須遵守各項國際品質標準，這需要投入大量且持續的資源。這些法規的複雜性可能導致核准流程冗長，並增加供應鏈的脆弱性，可能阻礙市場的持續成長。

市場促進因素

推動市場成長的主要動力是中小型生物製藥研發公司的增加，這從根本上改變了外包格局。與傳統的大型製藥企業不同，這些新興企業通常擁有強大的研發管線，但缺乏商業規模固態製劑生產所需的資本密集基礎設施。因此，它們正與契約製造建立策略合作夥伴關係，以在無需承擔高額固定成本的情況下推動研發。對早期藥物發現研究的大力投資進一步強化了這種依賴。根據Harris Williams R&D 2024年8月發布的報告《製藥合約服務：新數據顯示復甦跡象》，生技公司和中小製藥公司的研發支出預計將成長9%至12%，超過大型產業參與者的成長速度。這種資金流入直接轉化為固體製劑供應商合約量的增加，這些供應商能夠提供靈活的端到端開發服務。

同時，處理高活性藥物原料藥(HPAPI) 和複雜製劑技術的能力不斷提升，正在重塑產業的技術需求。隨著現代藥物研發轉向癌症治療和罕見疾病治療，分子活性不斷增強，但生物利用度低使得製劑開發面臨挑戰，迫使製造商投資於專用密閉設備和先進的增溶技術。根據龍沙公司於 2025 年 1 月發布的《2024 會計年度全年報告》，該公司小分子業務在 2024 年實現了 9.3% 的銷售成長。這一業績得益於其產品組合持續向提供高以金額為準、複雜服務轉型。傳統化學的持續主導地位也支撐了這一趨勢。龍沙公司預計，到 2025 年，小分子化合物仍將佔全球臨床開發平臺中所有分子的 54%，這需要持續的專業化生產能力。

市場挑戰

全球口服固態製劑（OSD）契約製造市場不斷擴張，但在應對嚴格的全球法規環境方面面臨著許多挑戰。由於合約研發生產機構（CDMO）的業務遍及多個司法管轄區，它們必須遵守各國衛生監管機構制定的不同品質標準和文件要求。這種分散性導致企業需要維持大規模的品質保證團隊，並且常常需要重複的測試通訊協定，從而顯著增加營運成本並降低利潤率。因此，原本可以用於擴大產能或升級設施的資源，但現在卻不得不用於維持持續的合規性。

監管壓力日益增加，這點從近期有關設施監管的行業數據中可見一斑。據歐洲製藥工業協會聯合會（EFPIA）稱，2024年因特定合規問題而進行的「基於理由」的檢查和評估頻率將比上一年加倍。監管力道的迅速加強造成了不穩定的商業環境，核准進度難以預測。這種不確定性阻礙了製造商按時交付的能力，並最終限制了他們高效拓展市場以滿足不斷成長的全球需求的能力。

市場趨勢

連續生產技術的快速普及正在從根本上改變口服固態製劑的生產環境，以完全整合的流式系統取代傳統的間歇式生產流程。這種營運模式的轉變使契約製造製造商能夠大幅縮短研發時間和減少生產面積，同時透過即時監控提高產品品質。這些能力對於處理日益增多的精準藥品和實現靈活的小批量生產至關重要。根據Hovione公司2025年10月發布的新聞稿《Hovione完成新澤西州製造地業務擴張的首期1億美元投資》，該公司已完成大規模的設施擴建項目，該項目明確整合了商業規模的連續片劑生產能力，以滿足其北美製藥客戶不斷變化的技術需求。

此外，隨著越來越多的公司尋求降低地緣政治風險並減少對分散的全球網路的依賴，策略性地將生產供應鏈遷回國內或近岸外包已成為行業優先事項。這一趨勢正促使口服固態製劑產能大規模轉移至美國和歐洲的國內工廠，以確保基本藥物的穩定供應。因此，大型製藥企業正在對當地基礎設施進行巨額投資，以建立強大且永續的生產生態系統。根據Think Global Health於2025年11月發表的題為《追蹤美國為規避關稅而進行的本土化進展》的報導，13家領先的製藥公司已聯合承諾在未來十年內投資超過4800億美元，以擴大其在美國的生產能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類型（片劑、膠囊、粉末、顆粒劑、其他）
    • 按最終用戶分類（大型企業、中小企業、Start-Ups、學名藥生產商）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲口服固態製劑（OSD）契約製造市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球口服固態製劑（OSD）契約製造市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH,
  • PerkinElmer Inc.
  • Pyramid Laboratories Inc.
  • Siegfried AG

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 18969

The Global Oral Solid dosage (OSD) Contract Manufacturing Market is projected to expand significantly, growing from USD 41.02 Billion in 2025 to USD 60.77 Billion by 2031, representing a CAGR of 6.77%. This sector involves the outsourcing of solid drug formulation production, including tablets and capsules, to specialized third-party vendors. The market is primarily driven by pharmaceutical companies aiming to achieve cost efficiencies and access advanced technologies for complex compounds without incurring heavy capital expenditures. Furthermore, the expiration of patents for major drugs has necessitated increased external capacity to handle high-volume generic production. According to the Association for Accessible Medicines, generic and biosimilar medicines accounted for 90% of all prescriptions filled in the United States in 2024, highlighting the critical volume demand fueling the contract manufacturing sector.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 41.02 Billion
Market Size 2031USD 60.77 Billion
CAGR 2026-20316.77%
Fastest Growing SegmentGranules
Largest MarketNorth America

However, the industry faces significant hurdles due to a stringent global regulatory environment. Contract manufacturers are required to maintain compliance with divergent international quality standards, which necessitates substantial and ongoing resource allocation. This regulatory complexity can lead to prolonged approval timelines and vulnerabilities within the supply chain, acting as a potential barrier to the market's sustained expansion.

Market Driver

A primary engine for market growth is the proliferation of small and mid-sized biopharmaceutical innovators, which is fundamentally transforming the outsourcing landscape. Unlike traditional large pharmaceutical entities, these emerging firms typically possess robust research pipelines but lack the capital-intensive infrastructure necessary for commercial-scale solid dose production. Consequently, they form strategic partnerships with contract manufacturers to navigate development phases without facing high fixed costs. This reliance is intensified by aggressive investment in early-stage discovery; according to the August 2024 report 'Outsourced Pharma Services: New Data Shows Resurgence Is Underway' by Harris Williams, R&D spending for biotech and small to mid-sized pharmaceutical companies is projected to increase by 9% to 12%, outpacing the growth rate of larger industry players. This capital influx directly translates into higher contract volumes for OSD providers capable of offering flexible, end-to-end development services.

Simultaneously, the expansion of capabilities for High-Potency Active Pharmaceutical Ingredients (HPAPIs) and complex formulations is reshaping technical requirements within the sector. As modern drug discovery shifts toward oncology and rare diseases, molecules are becoming increasingly potent and challenging to formulate due to poor bioavailability, compelling manufacturers to invest in specialized containment and advanced solubility enhancement technologies. In its 'Full-Year Report 2024' released in January 2025, Lonza reported that its Small Molecules division achieved sales growth of 9.3% in 2024, a performance driven by the continued portfolio shift toward high-value, complex service offerings. This trend is underpinned by the enduring dominance of traditional chemistries; according to Lonza, in 2025, small molecules continue to comprise 54% of all molecules in the global clinical development pipeline, necessitating sustained specialized manufacturing capacity.

Market Challenge

The expansion of the Global Oral Solid Dosage (OSD) Contract Manufacturing Market faces a formidable obstacle in navigating a stringent global regulatory environment. As contract development and manufacturing organizations (CDMOs) operate across multiple jurisdictions, they must align with divergent quality standards and documentation requirements enforced by different national health authorities. This fragmentation necessitates the maintenance of extensive quality assurance teams and often requires duplicative testing protocols, which significantly increases operational costs and erodes profit margins. Consequently, resources that could be invested in capacity expansion or facility upgrades are instead diverted toward maintaining continuous compliance.

The intensifying pressure of this regulatory burden is evident in recent industry data regarding facility oversight. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), in 2024, the frequency of 'for cause' inspections-assessments triggered by specific compliance concerns-doubled compared to the previous year. This sharp increase in regulatory scrutiny creates a volatile operating environment where approval timelines are unpredictable. Such uncertainty hampers the ability of manufacturers to guarantee strict delivery schedules, ultimately constraining the market's ability to scale efficiently in response to rising global demand.

Market Trends

The accelerated adoption of continuous manufacturing technologies is fundamentally changing the production landscape for oral solid dosages by replacing traditional batch processes with fully integrated flow systems. This operational shift allows contract manufacturers to significantly reduce development timelines and footprint requirements while enhancing product quality through real-time monitoring. Such capabilities are increasingly critical for handling the growing volume of precision medicines and facilitating flexible small-volume production. According to Hovione's October 2025 press release, 'Hovione Completes Initial $100M Investment Cycle to Expand U.S. Operations at New Jersey Manufacturing Site,' the company finalized a major facility expansion that explicitly integrates commercial-scale continuous tableting capacity to meet the evolving technical demands of North American pharmaceutical clients.

Additionally, strategic reshoring and nearshoring of manufacturing supply chains have become a primary priority for the industry as companies seek to mitigate geopolitical risks and reduce dependency on fragmented global networks. This trend is driving a substantial migration of oral solid dosage production capacity back to domestic hubs in the United States and Europe to ensure supply security for essential medicines. Consequently, large pharmaceutical entities are directing massive capital inflows into local infrastructure to establish robust and self-reliant production ecosystems. According to the November 2025 article 'Tracking Pharma's Progress on U.S. Onshoring Efforts to Avoid Tariffs' by Think Global Health, thirteen major pharmaceutical companies have collectively pledged more than $480 billion in investments toward expanding U.S. manufacturing capabilities over the next decade.

Key Market Players

  • AbbVie Inc.
  • Acino International AG
  • Aenova Holding GmbH
  • Beximco Pharmaceuticals Ltd
  • Boehringer Ingelheim International GmbH
  • Catalent Inc.
  • Corden Pharma International GmbH,
  • PerkinElmer Inc.
  • Pyramid Laboratories Inc.
  • Siegfried AG

Report Scope

In this report, the Global Oral Solid dosage (OSD) Contract Manufacturing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Solid dosage (OSD) Contract Manufacturing Market, By Product

  • Tablets
  • Capsules
  • Powders
  • Granules
  • Others

Oral Solid dosage (OSD) Contract Manufacturing Market, By End User

  • Large-size companies
  • Small & medium size companies
  • Startups
  • generic pharmaceutical companies

Oral Solid dosage (OSD) Contract Manufacturing Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Solid dosage (OSD) Contract Manufacturing Market.

Available Customizations:

Global Oral Solid dosage (OSD) Contract Manufacturing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Tablets, Capsules, Powders, Granules, Others)
    • 5.2.2. By End User (Large-size companies, Small & medium size companies, Startups, generic pharmaceutical companies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By End User

7. Europe Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By End User
    • 7.3.2. France Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By End User

8. Asia Pacific Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By End User
    • 8.3.2. India Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By End User

9. Middle East & Africa Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By End User

10. South America Oral Solid dosage (OSD) Contract Manufacturing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Oral Solid dosage (OSD) Contract Manufacturing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Oral Solid dosage (OSD) Contract Manufacturing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Acino International AG
  • 15.3. Aenova Holding GmbH
  • 15.4. Beximco Pharmaceuticals Ltd
  • 15.5. Boehringer Ingelheim International GmbH
  • 15.6. Catalent Inc.
  • 15.7. Corden Pharma International GmbH,
  • 15.8. PerkinElmer Inc.
  • 15.9. Pyramid Laboratories Inc.
  • 15.10. Siegfried AG

16. Strategic Recommendations

17. About Us & Disclaimer